Jamie E. Chaft, MD

Articles

Dr. Chaft on the Rationale for the OPAL Trial in EGFR+ NSCLC

November 23rd 2020

Jamie E. Chaft, MD, discusses the rationale behind the OPAL trial in EGFR-mutant non–small cell lung cancer.

Dr. Chaft on the Next Steps of Osimertinib Research in EGFR+ NSCLC

November 20th 2020

Jamie E. Chaft, MD, a thoracic medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the next steps of osimertinib research in EGFR-mutant non–small cell lung cancer.

Dr. Chaft on Predictive Biomarkers in Lung Cancer

July 6th 2020

Jamie E. Chaft, MD, discusses predictive biomarkers in lung cancer.

Dr. Chaft on Considerations for Restarting Immunotherapy in Lung Cancer

June 10th 2020

Jamie E. Chaft, MD, discusses considerations for restarting immunotherapy in patients with lung cancer.

Dr. Chaft on Considerations for Restarting Immunotherapy in Lung Cancer

June 9th 2020

Jamie E. Chaft, MD, discusses considerations for restarting immunotherapy in patients with lung cancer.

Dr. Chaft on the Emergence of Immunotherapy in Stage IV Lung Cancer

May 21st 2020

Jamie E. Chaft, MD, discusses the emergence of immunotherapy in stage IV lung cancer.

Dr. Chaft on the Emergence of Immunotherapy in Stage IV Lung Cancer

May 20th 2020

Jamie E. Chaft, MD, discusses the emergence of immunotherapy in stage IV lung cancer.

Dr. Chaft on Immune-Related AEs in NSCLC

May 15th 2020

Jamie E. Chaft, MD, discusses immune-related adverse effects in non–small cell lung cancer.

Dr. Chaft on the Rise of Immunotherapy in Lung Cancer

February 8th 2020

Jamie E. Chaft, MD, discusses the rise of immunotherapy in lung cancer and research with this treatment modality that is on the horizon.

Dr. Chaft on Investigational Neoadjuvant Immunotherapy Approaches in NSCLC

November 18th 2019

Jamie E. Chaft, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses investigational neoadjuvant immunotherapy approaches in non–small cell lung cancer (NSCLC).